Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

MLA

Hughes, T. P., et al. “Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.” New England Journal of Medicine, vol. 381, no. 24, Dec. 2019, pp. 2315–26. EBSCOhost, https://doi.org/10.1056/NEJMoa1902328.

APA

Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., Breccia, M., Goh, Y.-T., Talpaz, M., Hochhaus, A., Coutre, P. le, Ottmann, O., Heinrich, M. C., Steegmann, J. L., Deininger, M. W. N., Janssen, J. J. W. M., Mahon, F.-X., Minami, Y., Yeung, D., & Ross, D. M. (2019). Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. New England Journal of Medicine, 381(24), 2315–2326. https://doi.org/10.1056/NEJMoa1902328

Chicago

Hughes, T. P., M. J. Mauro, J. E. Cortes, H. Minami, D. Rea, D. J. DeAngelo, M. Breccia, et al. 2019. “Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.” New England Journal of Medicine 381 (24): 2315–26. doi:10.1056/NEJMoa1902328.